Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody

Arthritis Care and Research

Volumn 64, Issue 10, 2012, Pages 1602-1610

  Cao, Hua ^a   Pan, Meng ^a   Kang, Yanqing ^a   Xia, Qunli ^a   Li, Xia ^a   Zhao, Xiaoqing ^a   Shi, Ruofei ^a   Lou, Jianghua ^a   Zhou, Min ^a   Kuwana, Masataka ^b   Ding, Xiaoyi ^a   Zheng, Jie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASES AFFECTING THE SKIN; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RESPIRATORY FAILURE; SKIN ULCER;

ADULT; AGED; AUTOANTIBODIES; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84869154654     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21728     Document Type: Article

References (35)

1. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46: 626-36.
2. Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 2009; 28: 979-84.
3. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234-9. (Pubitemid 43372323)
4. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-22. (Pubitemid 35461314)
5. Mileti LM, Strek ME, Niewold TB, Curran JJ, Sweiss NJ. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol 2009; 15: 254-5.
6. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48: 607-12.
7. Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008; 4: 201-9.
8. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19: 523-9. (Pubitemid 47530870)
9. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6. (Pubitemid 40663949)
10. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation- associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-200.
11. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti- CADM-140 antibody. Rheumatology (Oxford) 2010; 49: 433-40.
12. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223.
13. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
14. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibodyassociated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49: 1713-9.
15. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
16. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100: 124S-7S. (Pubitemid 23035918)
17. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-64.
18. Ichikado K, Suga M, Muranaka H, Gushima Y, Miyakawa H, Tsubamoto M, et al. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology 2006; 238: 321-9. (Pubitemid 43010610)
19. Ichikado K, Suga M, Muller NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 2002; 165: 1551-6. (Pubitemid 34606673)
20. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136: 1341-7.
21. Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010; 162: 669-73.
22. Cox NH, Coulson JH. Diagnosis of skin disease. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology, vol. 1. 7th ed. Malden (MA): Blackwell Publishing Limited; 2010. p. 5.1.
23. Kawachi Y, Maruyama H, Furuta J, Fujisawa Y, Nakamura Y, Takahashi T, et al. Cutaneous deep necrosis with dermatomyositis: correlation with interstitial pneumonia. Eur J Dermatol 2007; 17: 345-6. (Pubitemid 47051560)
24. Burnouf M, Mahe E, Verpillat P, Descamps V, Lebrun-Vignes B, Picard-Dahan C, et al. Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol 2003; 130: 313-6. (Pubitemid 36542230)
25. Mautner GH, Grossman ME, Silvers DN, Rabinowitz A, Mowad CM, Johnson BL Jr. Epidermal necrosis as a predictive sign of malignancy in adult dermatomyositis. Cutis 1998; 61: 190-4. (Pubitemid 128472601)
26. Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, Mouthon L, et al. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162: 337-44.
27. Bonnefoy O, Ferretti G, Calaque O, Coulomb M, Begueret H, Beylot-Barry M, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004; 49: 235-44. (Pubitemid 38210135)
28. Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial highresolution CT findings and functional correlation. Chest 2003; 123: 1096-103. (Pubitemid 36444366)
29. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 2011; 105: 1380-7.
30. Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol 2011. E-pub ahead of print.
31. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-5.
32. Yoneyama M, Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J Biol Chem 2007; 282: 15315-8. (Pubitemid 47093255)
33. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of newonset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999; 116: 1168-74. (Pubitemid 29535965)
34. Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 2011; 21: 223-7.
35. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-33.